DUBLIN--(BUSINESS WIRE)--The "Global Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
The Global Cell and Gene Therapy Market is expected to grow at a compound annual growth rate (CAGR) of 26.40% from 2023 through 2028.
The scope of this study encompasses an investigation of the cell and gene therapy market. The report analyzes cell and gene therapy market based on therapy type, product, application, and region. The publisher determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next five years.
The increasing focus on developing advanced therapies for different therapeutic areas, and growing prevalence of chronic conditions such as cancer and rare diseases, are responsible for market growth.
The market has witnessed approval of therapies in 2022 and 2023. Treatments approved in 2022 include Adstiladrin from Ferring Pharmaceuticals, Hemgenix from CSL Behring and UniQure, Roctavian from Biomarin Pharmaceuticals, Elevidys from Sarepta and Roche, and Upstaza from PTC Therapeutics. Vyjuvek from Krystal Biotech and Lyfgenia from Bluebird Bio were approved in 2023. There are more companies which have submitted biologics license applications for their cell and gene therapy products and the approvals are expected in 2024, thus contributing to the growth of the market.
Products such as Kresladi from Rocket Pharmaceuticals and Fidanacogene elaparvovec from Pfizer have submitted the biologics license application (BLA) and are likely to get approval in March and April 2024.
The report also includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on the emerging technologies, and new developments, ESG development and investment outlook.
Report Includes
- 55 data tables and 26 additional tables
- An overview of the global market for cell and gene therapy
- Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market's size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
- An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
- Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
- Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
- Profiles of leading market participants, including Mallinckrodt PLC, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.
Company Profiles
- Amgen Inc.
- Bluebird Bio Inc.
- Bristol-Myers Squibb Co.
- Dendreon Pharmaceuticals Llc
- Ferring Pharmaceuticals
- Gilead Sciences Inc.
- Iovance Biotherapeutics Inc.
- Johnson & Johnson Services Inc.
- Krystal Biotech Inc.
- Mallinckrodt Plc
- Novartis Ag
- Orchard Therapeutics Plc.
- Pharmicell Co. Ltd.
- Uniqure N.V.
- Vericel Corp.
Key Topics Covered:
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Value
Chapter 2 Market Overview
- Cell and Gene Therapy Overview
- Regulatory Landscape
- U.S. (FDA)
- Europe
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
Chapter 4 Market Segmentation Analysis
- Segmentation Breakdown
- Global Market for Cell and Gene Therapy
- Market Size and Forecast
- Market Analysis
- Cell Therapy
- Gene-modified Cell Therapy
- Gene Therapy
- Global Market for Gene-modified Cell Therapy and Gene Therapy by Vector Type
- Market Size and Forecast
- Market Analysis
- Adeno-Associated Viral (AAV) Vectors
- Retroviral Vectors
- Lentiviral Vectors
- Others
- Global Market for Cell and Gene Therapy by Drug Product
- Market Size and Forecast
- Zolgensma
- Yescarta
- Kymriah
- Abecma
- Maci
- Tecartus
- Epicel
- Others
- Global Market for Cell and Gene Therapy by Application
- Market Size and Forecast
- Oncology
- Rare Diseases
- Ophthalmology
- Other Therapeutic Areas
- Geographic Breakdown
- Global Market for Cell and Gene Therapy by Region
- Market Size and Forecast
- North America
- Market Size and Forecast
- U.S.
- Canada
- Mexico
- Europe
- Market Size and Forecast
- Germany
- U.K.
- France
- Rest of Europe
- Asia-Pacific
- Market Size and Forecast
- Japan
- China
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Market Size and Forecast
Chapter 5 Competitive Intelligence
- Investment Outlook
- Mergers and Acquisitions
- Competitive Landscape: Overview
- Market Share Analysis
- Strategic Acquisitions and Collaborations
- Pipeline Analysis
Chapter 6 Sustainability: An ESG Perspective
- Introduction
- Conclusion
Chapter 7 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/k3hrv2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
